3 Healthcare Stocks That Win Regardless of Fed Rate Hikes

Wall Street is bracing for further Federal Reserve rate hikes amid rising bond yields and persistent inflation, but three healthcare stocks—Eli Lilly, Medtronic, and Johnson & Johnson—are positioned to perform well regardless of the central bank's next move. Healthcare demand remains resilient to interest rate changes because people prioritize medical care over cost concerns. Eli Lilly is leveraging its dominant GLP-1 weight-loss drug franchise to diversify into autoimmune, mental health, and infectious disease treatments through recent acquisitions. Medtronic has accelerated growth after a restructuring, with fiscal 2026 sales up 8.4% and first-quarter 2027 growth near 14%, while maintaining a 49-year dividend increase streak. Johnson & Johnson offers broad pharmaceutical and medical device exposure with a dividend raised annually for over six decades. These companies are considered well-run businesses with strong growth opportunities in any economic environment, making them attractive for investors seeking stability ahead of potential rate hikes.